[{"indications": "Indications\u00a0iontophoretic treatment of hyperhidrosis;\r\nother indications section 15.1.3", "name": "GLYCOPYRRONIUM BROMIDE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "13 Skin", "13.12 Antiperspirants"], "cautions": "Cautions\u00a0see section 15.1.3 (but poorly absorbed and systemic\r\neffects unlikely)", "side-effects": "Side-effects\u00a0see section 15.1.3 (but poorly absorbed and systemic\r\neffects unlikely), tingling at administration site", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/106187.htm", "doses": ["Consult product literature; only 1 site to be treated\r\nat a time, max. 2 sites treated in any 24 hours, treatment not to\r\nbe repeated within 7 days"]}, {"indications": "Indications\u00a0iontophoretic treatment of hyperhidrosis;\r\nother indications section 15.1.3", "name": "GLYCOPYRRONIUM BROMIDE - ANTIPERSPIRANTS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "13 Skin", "13.12 Antiperspirants"], "cautions": "Cautions\u00a0see section 15.1.3 (but poorly absorbed and systemic\r\neffects unlikely)", "side-effects": "Side-effects\u00a0see section 15.1.3 (but poorly absorbed and systemic\r\neffects unlikely), tingling at administration site", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/106187.htm", "doses": ["Consult product literature; only 1 site to be treated\r\nat a time, max. 2 sites treated in any 24 hours, treatment not to\r\nbe repeated within 7 days"]}, {"indications": "Indications\u00a0drying secretions\r\n(see Prescribing in Palliative\r\nCare); premedication; intra-operative bradycardia; with neostigmine for reversal of non-depolarising neuromuscular block; hyperhidrosis\r\n(section 13.12)", "name": "GLYCOPYRRONIUM BROMIDE - ANTIMUSCARINIC DRUGS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "15 Anaesthesia", "15.1 General anaesthesia", "15.1.3 Antimuscarinic drugs", "GLYCOPYRRONIUM BROMIDE"], "cautions": "Cautions\u00a0section 1.2", "side-effects": "Side-effects\u00a0section 1.2", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/6590.htm", "doses": ["Premedication, by intramuscular or intravenous injection, 200\u2013400\u00a0micrograms or 4\u20135\u00a0micrograms/kg (max. 400\u00a0micrograms); child 1 month\u201312 years, 4\u20138\u00a0micrograms/kg (max. 200\u00a0micrograms)", "Intra-operative bradycardia, by intravenous\r\ninjection, 200\u2013400\u00a0micrograms or 4\u20135\u00a0micrograms/kg\r\n(max. 400\u00a0micrograms), repeated if necessary; child 1 month\u201318 years, 4\u20138\u00a0micrograms/kg (max. 200\u00a0micrograms), repeated\r\nif necessary", "Control of muscarinic side-effects of neostigmine in reversal of non-depolarising neuromuscular block, by intravenous\r\ninjection, 200\u00a0micrograms per 1\u00a0mg of neostigmine, or 10\u201315\u00a0micrograms/kg; child 1 month\u201312 years, 10\u00a0micrograms/kg (max. 500\u00a0micrograms)"]}]